CJRS-10671 and CJRS-10672, biotherapeutic candidates with promising antitumor efficacy in vivo April 25, 2022
EGFR-TKI TAS-3351 overcomes T790M and C797S mutations tied to NSCLC treatment resistance April 25, 2022
AUR-103 in combination with azacytidine and bortezomib for myeloma and leukemia treatment April 20, 2022
RSS